119 results about "Glipizide" patented technology

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load.

The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.

The invention discloses a diabecron and glipizide -containing slow-release agent and the method for preparing the same. The glipizide micro-pill takes blank micro-pill as carrier, and combines glipizide and other medical findings with it. The diabecron-containing slow-release micro-pill comprises diabetosan pill, slow-release coating membrane material or other medical findings. The method for preparing diabecron-containing slow-release micro-pill takes extrusion rolling method or blank micro-pill loading method. The product is characterized by safety, high efficient, low toxicity and convenient usage. It can be used to treat non-insulin-dependent diabetes mellitus.

The invention relates to a novel synthesis route of glipizide, which is characterized by comprising the following steps of protecting 4-(2-amino ethyl)benzenesulfonic acid ammonia (II) by Boc anhydride to obtain a compound (III); reacting the compound (III) with cyclohexyl isocyanate to obtain a compound (IV); carrying out deprotection on the compound (IV) to obtain a compound (V); and reacting the compound (V) with 2-methyl-5-pyrazine carboxylic acid to obtain the glipizide (I) with the single impurity which is less than or equal to 0.5% and the high purity which is more than or equal to 99%. The process is simple, the yield is high, the purity is high and the single impurity is low; and the process is environment-friendly and industrial production is easy to realize.

The preparation method of metformin hydrochloride glipizide capsule includes the following steps: using 250-500 weight portions of metformin hydrochloride, sieving it by using sieve with 100 meshes, using 2.5 weight portions of glipizide, sieving it by using sieve with 200 meshes or pulverizing it to make its fineness greater than 200 meshes, then uniformly mixing the above-mentioned materials, using dilute ethyl alcohol solution of polyvidone as adhesive, making soft material, granulating by using sieve with 24 meshes, drying at 50-60deg.C, finishing granules by using sieve with 20 meshes, adding 1% of magnesium stearate and capsulizing so as to obtain the invented finished product.

The invention relates to a preparation method of a glipizide osmotic pump controlled release tablet. A glipizide tablet core is prepared by the following steps of semipermeable membrane wrapping, laser boring and damp-proof layer wrapping. The preparation method is characterized in that the preparation of the glipizide tablet core comprises preparation of solid dispersoid and preparation of the tablet core. In the preparation method, a solid dispersion technology is utilized, so that the dissolving speed of medicines is improved; the solubility of the glipizide is improved through the fluxing auxiliary materials; and a proper amount of penetration promoter is added to adjust the osmotic pressure so as to achieve constant-speed or approximately-constant-speed release. The invention has the advantages that the process is simple, the cost is low, the release tablet is easy to accept by patients and the treating effect is good.

An orally disintegrating hypoglycemic tablet is prepared from glipizide, filler, disintegrant, flavouring, lubricant and adhesive. Its advantage is short disintegrating time (less than 60 S). Its preparing process is also disclosed.

The invention discloses a metformin hydrochloride and glipizide sustained-release pellet and a preparation method thereof. In the preparation method, a sustained release coated pellet of the metformin hydrochloride and a sustained release pellet of the glipizide are prepared respectively; and the two pellets are filled in capsules in a proportion of 250g-500g of the metformin hydrochloride and 2.5g-10g of the glipizide in every 1000 capsules; wherein, the coated pellet of the metformin hydrochloride is prepared by pill pericardium sustained release coating membrane; the sustained release pellet of the glipizide is prepared directly by extrusion-spheronization method. In the invention, the two pellets are filled into one capsule, thereby being convenient for quality control; octodecyl alcohol is taken as sustained release material for the sustained-release pellet of the glipizide, which is convenient for the forming of the pellet so as to reduce bursting release effectively. The metformin hydrochloride and the glipizide slowly release a drug within 12 hours, which reduces the frequency of taking medicine, stabilizes blood concentration better and reduces untoward effect, thereby having good marketing prospect.

The invention discloses a glipizide sustained-release granule and a preparation method thereof. The glipizide sustained-release granule is mainly prepared from glipizide bulk drugs, sustained-release materials and other appropriate auxiliary materials. The glipizide sustained-release granule can deaccelerate the release rate of main drugs, reduce the frequency of administration and improve the patient compliance. The glipizide sustained-release granule provided by the invention has the advantages of high quality controllability and stability of the preparation process.

The invention relates to glipizide tablets for treating diabetes, belonging to the technical field of Western medicine preparations. The glipizide tablets consist of the following components: 5-15 parts of glipizide, 20-40 parts of hydroxypropyl methyl cellulose, 30-50 parts of calcium carbonate and the like; and the components are mixed by a specific particle stirrer. The tablets provided by the invention are stably and slowly released.

The invention belongs to the field of medicines and particularly relates to glipizide tablets and a preparation method thereof. The glipizide tablets comprise raw materials in parts by weight as follows: 4-6 parts of glipizide, 87-263 parts of a filler, 5-15 parts of a disintegrating agent and 0.5-1.5 parts of a lubricant, wherein the filler preferably comprises components in parts by weight as follows: 24-72 parts of starch, 15-45 parts of mannitol, 26-78 parts of sugar and 22-68 parts of microcrystalline cellulose. The glipizide tablets have stable drug release property and high dissolution rate. The invention further provides the preparation method of the glipizide tablets. The preparation method has a simple and reasonable process and is easy to implement.

The invention provides a glipizide osmotic pump type controlled release tablet. The controlled release tablet adopts ethylene cellulose and polyvidone as semi-permeable membrane materials and is unsymmetrical in appearance, not only can overcome the defect that a semi-permeable membrane is aged and reduce the drug release residue, but also can simplify the identification of laser drilling and is stable to place when being conveyed on a conveyor belt; and a hole is easier to be drilled in the middle to facilitate the stable release of the drugs. The invention also provides a method for improving the aging resistance of the glipizide osmotic pump type controlled release tablet, which is characterized in that the ethylene cellulose-the polyvidone is adopted as the semi-permeable membrane material. In addition, the invention further provides an application of an ethylene cellulose-the polyvidone combination for preparing the aging resistance of the glipizide osmotic pump type controlled release tablet.

An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.

The invention relates to a glipizide controlled release composition which consists of a double-layer tablet core and a semipermeable membrane controlled release coating membrane. The double-layer tablet core consists of a medicine containing layer and a boosting layer, wherein the medicine containing layer and the boosting layer of the composition are pelletized by a water suspension. The invention further relates to a preparation method of the glipizide controlled release composition. The preparation method comprises the following steps: pelletizing the medicine containing layer; pelletizing the boosting layer; preparing the double-layer tablet core; coating; and punching, wherein the medicine containing layer and the boosting layer are pelletized by the water suspension. The glipizide controlled release composition prepared by the preparation method provided by the invention is uniform in particle distribution, good in tabletting and forming effect, uniform in content, low in residual rate of organic solvents and good in dissolving out effect. The preparation method is simple and feasible and is favorable for industrial production.

The invention discloses a qualitative analysis detection method for illegally mixed high-polar chemical anti-diabetic components in anti-diabetic traditional Chinese medicine products. The method comprises the following steps that: 1) high efficient liquid phase chromatography conditions: an ammonium acetate-triethylamine-acetonitrile moving phase system and a C18 chromatographic column with certain specification are used, the wavelength is detected by ultraviolet, and the flow rate is 1.0ml / min; 2) analysis result: glibenclamide, glipizide, gliclazide, glimepiride, gliquidone, repaglinide, nateglinide, rosiglitazone and pioglitazone hydrochloride can realize the complete separation; 3) result judgment: when retention time of a chromatographic peak in an anti-diabetic traditional Chinese medicine product is consistent with that of anti-diabetic medicine in the step 2) and the apparent absorption is shown out, which indicate that the anti-diabetic medicine is contained in the sample to be tested. The method has the advantages of quickness, simplicity, convenience, high sensitivity, strong specialization, broad coverage and so on.

The invention relates to a glipizide film-controlled slow-release pellet capsule. A slow-release film of the glipizide film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the glipizide film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose, lactose and sodium dodecyl sulfate, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 17 to 36%. The glipizide film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the glipizide film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the glipizide film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

Disclosed is a glipizide osmotic pump controlled release tablet. The glipizide osmotic pump controlled release tablet comprises, from inside to outside, a double-layer tablet core containing a drug layer and a promoting layer and an insoluble semi-permeable membrane; the drug layer comprises drug release holes and an optional moisture-proof film coating; the drug layer, based on the total weight, contains 1-30 wt.% of glipizide, 30-95 wt.% of a suspending agent, 2-30 wt.% of a retardant, 0-10 wt.% of an adhesive, 0-2 wt.% of a colorant and 0-2 wt.% of a lubricant; the promoting layer, based on the total weight, comprises 30-80 wt.% of an expanding agent, 1-30 wt.% of a retardant, 0-2 wt.% of a colorant, 5-40 wt.% of an osmotic pressure active substance and 0-1 wt.% of a lubricant; and the weight gain of the semi-permeable membrane is 5-20% of the weight of the tablet core. The invention also discloses a preparation method of the glipizide osmotic pump controlled release tablets. The method is convenient for production, and the product is easy to store, and can better achieve the purpose of controlled release.

The invention relates to a glibenclamide, gliclazide and glipizide triple test card and a test method thereof, belonging to the technical field of testing of western medicine components which are illegally added into traditional Chinese medicines. A test bar is arranged in a shell of the triple test card and comprises a sample pad, a plurality of sections of colloidal gold membranes, a nitrocellulose membrane and a water-absorbing membrane which are sequentially stuck on a supporting backboard, wherein the plurality of sections of the colloidal gold membranes are glass fiber membranes containing colloidal gold markers of an anti-glibenclamide antibody, an anti-gliclazide antibody and an anti-glipizide antibody sequentially, three test strips which respectively contain a glibenclamide protein conjugate, a gliclazide protein conjugate and a glipizide protein conjugate are arranged on the nitrocellulose membrane, and the triple test card additionally comprises a quality control strip containing an anti-rabbit antibody or an anti-mouse antibody. The triple test card has the advantages of being capable of simultaneously detecting glibenclamide, gliclazide and glipizide which are illegally added in a glucose-lowering traditional Chinese medicine. The test card is easy for preparation, convenient and fast for use and accurate in result, and can be used for saving the test cost.

The invention belongs to the technical field of bulk pharmaceutical chemical preparation and particularly relates to a preparation method of glipizide crystals. According to the technical scheme, the preparation method comprises the first step that glipizide is added into an isopropanol mixed solvent, the solid-to-liquid ratio of the solution is 0.05 g / ml to 0.1 g / ml, and stirring is conducted continuously for 30-60 minutes at the temperature of 40-45 DEG C for dissolution; the second step that dilute alkaline liquor is added, the pH of the solution is regulated to 8-9, and filtering and decoloring are conducted; the filtrate is transferred into a crystallizer, a hydrochloric acid solution is added, the pH of the solution is regulated to 6-7, seed crystals are added and cultured for 1-2 h, then the temperature is dropped to 5-10 DEG C, and the crystals are cultured for 1-3 h; filtering is conducted, a cleaning solvent is used for washing filter cakes, products are dried, and the high-granularity glipizide products are obtained. According to the preparation method of the high-granularity glipizide crystals, the obtained products do not aggregate, the main granularity is 10 microns or above, and granularity distribution is uniform.

The present invention relates to an oral disintegrant freeze-dried tablet which can be quickly disintegrated in the mouth cavity and absorbed for reducing blood sugar effectively. It is made up by using glipizide as main medicine, adding filling agent, adhesive and correctives and making them undergo the process of freeze-drying treatment.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a prescription of a glipizide oral instant film and a preparation method thereof. The oral instant film comprises medical active ingredients and pharmaceutically adaptable auxiliary materials. The film comprises the following components in percentage by weight: 1-30% of glipizide, 40-80% of a macromolecular film-forming material, 0-30% of a plasticizer, 0-20% of a corrigent and 0-20% of other auxiliary materials. The film prepared by the glipizide film can be taken without water. The film placed in the oval cavity can be quickly dispersed and dissolved (equivalent to an oral solution) and is swallowed into stomach with saliva. After the film is orally taken, no disintegration process is available, so that the film has the advantages of being quick to absorb, quick to response and high in bioavailability. The product is accurate in dosage, and dust explosion in the production process is nearly avoided, so that the problem on labor protection and environmental pollution can be solved.

The invention relates to a compound sustained-release preparation composed of glipizide and metformin hydrochloride, and its preparing method. The weight ratio of glipizide to metformin hydrochloride is 1 : 100-200, the best ratio is 1:100 and it adds a proper amount of medicinal auxiliary to the preparation. The compound sustained-release tablet can not only make advantages complementation on glipizide and metformin hydrochloride, promote and increase secretion of beta-cell insulin, and raise the utilization of glucose in tissues, such as muscle, etc, but also reduce the stimulus of metformin hydrochloride to stomach intestine, and largely strengthen curative effect and drug application safety.

The invention discloses a glipizide enteric sustained-release preparation combination and a preparation method thereof. The glipizide enteric sustained-release preparation combination is mainly prepared from glipizide bulk drugs, sustained-release materials, enteric materials and other appropriate auxiliary materials. The glipizide enteric sustained-release preparation provided by the invention can not only prevent glipizide from disintegrating in the stomach and causing irritation to gastric mucosa and avoid the adverse reactions caused by the administration, such as nausea, abdominal pain, diarrhea and the like, but also deaccelerate the release rate of drugs, reduce the frequency of administration and improve the patient compliance. The invention provides a novel form of drug featuring higher safety and better patient compliance and having the advantages of high quality controllability and stability of the preparation process.

The invention belongs to the technical field of medicines and particularly relates to a glipizide compound as well as a pharmaceutical composition containing the glipizide compound and a preparation method of the glipizide compound. The glipizide compound has a structural formula shown in the specification, and the X-ray powder diffraction pattern, measured by virtue of Cu-Kalpha ray of the glipizide compound is shown in Figure 1. The glipizide compound provided by the invention is a novel crystalline form compound of glipizide, thus the water solubility of the compound can be significantly increased; and the purpose of synchronization release of a pharmaceutical composition comprising the compound and metformin hydrochloride can be achieved, in-vitro dissolution is excellent, the clinical curative effect of the pharmaceutical composition is equivalent to that of the commercially available bulk drug and the pharmaceutical composition has better security.

The invention belongs to the field of medicine detection, and relates to a method for using liquid chromatogram-tandem mass spectrometry to measure concentration of glipizide in plasma, in particularto a method for measuring the concentration of glipizide in plasma of a beagle. The method comprises the following steps of 1, preparation of a plasma sample; 2, sedimentation of protein; 3, measuringthrough the liquid chromatogram-tandem mass spectrometry. An interior label working solution gliclazide is added in the sample, and methyl alcohol is adopted for settling, volution and centrifuging.Then the liquid chromatogram-tandem mass spectrometry is adopted for measuring the concentration of glipizide in the plasma. The method adopts methyl alcohol for settling the protein, has the advantages that liquid chromatogram-tandem mass spectrometry is conducted, the operation is simple, the detection limit is low, and the repeatability is high, and is applicable to pharmacokinetic studies, toxicokinetic studies, bioequivalence studies and the like.

A slowly-or controllably-releasing semi-solid medicine for treating diabetes B is proportionally prepared from glipizide and slowly-releasing semi-solid skeleton carrier.